Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
复制标题
头颈部晚期鳞状细胞癌的联合化疗。
DOI：
10.1002/hed.2890040205
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
J. Hebel
中科院分区：
文献类型：
--
作者：
D. D. Coker;E. Elias;P. Chretien;W. Gray;J. J. Coleman;T. Zentai;M. Didolkar;D. Morris;T. Viravathana;J. Hebel
对51例晚期头颈部鳞状细胞癌患者（32例初治，19例初治）采用大剂量顺铂（DDP）、博莱霉素（Bleo）、+/-大剂量甲氨蝶呤（MTX）联合化疗。33例（65%）患者对治疗有反应;其中5例（10%）患者完全缓解。既往未接受治疗的患者和接受三种药物（DDP，Bleo和MTX）的患者的反应率最高。反应持续时间为8至12周。7例（15%）患者显示了两年生存率。所有无应答者均在两年内死于疾病。5例完全缓解患者中有3例（56%）和4例（21%）部分缓解患者存活两年。术前化疗在头颈癌中的作用尚未得到最终确定。
Fifty-one patients (32 previously untreated, 19 previously treated) with advanced squamous cell carcinoma of the head and neck received a single course of combination chemotherapy consisting of high dose cis-platinum (DDP), bleomycin (Bleo), +/- high dose methotrexate (MTX). Thirty-three (65%) patients responded to therapy; 5 (10%) of these patients had a complete response. Previously untreated patients and those who received the three drugs (DDP, Bleo and MTX) had the highest response rates. The duration of response was 8 to 12 weeks. Seven (15%) patients showed a two-year survival rate. All nonresponders were dead of disease within two years. Three (56%) of the five complete-response patients and 4 (21%) of the partial-response patients survived for two years. The role of preoperative chemotherapy in head and neck cancer is yet to be conclusively defined.